Education
About Us
Working with TipRanks
Follow Us
SOPHiA GENETICS (SOPH)
NASDAQ:SOPH
Earnings Data
Report Date
Aug 12, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.21Last Year’s EPS
-0.23Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 06, 2025
|% Change Since: -8.92%
|Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Positive
SOPHiA GENETICS demonstrated strong revenue growth and customer expansion, particularly in the U.S. market, alongside successful cost management and strategic partnerships. However, challenges in Latin America and the biopharma segment presented some headwinds.Company Guidance
During the SOPHiA GENETICS Q1 2025 earnings call, the company provided guidance that reflects promising growth and strategic advancements. Revenue increased by 15% on a constant currency basis and 13% on a reported basis, highlighting a return to near historical growth levels, with a specific focus on capitalizing on new customer signings and expanding in the U.S. market, where revenue from core genomic customers grew over 30% year-over-year. The company added 28 new customers in Q1 2025, contributing to an increase in platform analysis volume to approximately 93,000, representing an 11% year-over-year growth. SOPHiA GENETICS also achieved a record adjusted gross margin of 75.7%, up 520 basis points year-over-year, and delivered a 24% year-over-year improvement in adjusted EBITDA loss, which stood at $9.8 million for the quarter. The company reaffirmed its full-year revenue guidance for 2025 of $72 million to $76 million, representing 10% to 17% growth on a reported basis, and is optimistic about its path towards adjusted EBITDA breakeven by the end of 2026.Revenue Growth
Revenue grew 15% on a constant currency basis and 13% on a reported basis, reaching $17.8 million in Q1 2025 compared to $15.8 million in Q1 2024.
Increased Customer Base
SOPHiA GENETICS added 28 new customers in Q1 2025, increasing the total number of core genomic customers to 490.
U.S. Market Expansion
Revenue and analysis volume from U.S. core genomic customers grew over 30% year-over-year. Major expansions were announced at Henry Ford Hospital and Mayo Clinic.
Partnership Expansion with AstraZeneca
SOPHiA GENETICS expanded its partnership with AstraZeneca to deploy MSK-ACCES globally, extending the scope to 30 sponsored institutions.
Improved Gross Margin
Achieved a record 75.7% adjusted gross margin, up 520 basis points year-over-year.
Cost Management Success
Delivered a 24% year-over-year improvement to adjusted EBITDA loss, bringing it down to $9.8 million in Q1 2025.
Technology and Innovation
SOPHiA DDM analyzed over 2 million genomic patient profiles since inception, marking a significant milestone for the platform.
---
SOPH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SOPH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2025 | $3.14 | $3.00 | -4.46% |
Mar 04, 2025 | $3.57 | $3.10 | -13.17% |
Nov 05, 2024 | $3.75 | $3.75 | 0.00% |
Aug 06, 2024 | $4.15 | $4.06 | -2.17% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does SOPHiA GENETICS (SOPH) report earnings?
SOPHiA GENETICS (SOPH) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
What is SOPHiA GENETICS (SOPH) earnings time?
SOPHiA GENETICS (SOPH) earnings time is at Aug 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SOPH EPS forecast?
SOPH EPS forecast for the fiscal quarter 2025 (Q2) is -0.21.
---